TOP TIERMARKET NEWSWIRE
Movers explained · 2026-11-18

Archived explainer. For the current picture see today's RXRX page.

Why Is RECURSION PHARMACEUT A (RXRX) Stock Up Today?

By the Top Tier Newswire AI Desk · November 18, 2026 at 9:42 AM ET · reviewed against 6 wire stories

RECURSION PHARMACEUT A (RXRX) is up +6.99% in the latest session. Our newswire has captured 6 stories on RXRX across 4 sources in the last 36 hours, with AI sentiment reading bullish (avg 61/100).

Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.

Recursion Pharmaceuticals (RXRX) shares rose 6.99% to $2.91, driven by a formal agreement with the U.S. Food and Drug Administration regarding the design of a registrational Phase 3 trial. The company aligned with the regulator on the trial structure for REC-4881, a therapy for Familial Adenomatous Polyposis, a rare disease. This regulatory clarity provided a catalyst for the stock after a recent period of decline.

What Happened

Recursion Pharmaceuticals announced that it has reached an agreement with the FDA on the design of a registrational Phase 3 trial for REC-4881. The therapy targets Familial Adenomatous Polyposis, a genetic condition characterized by the growth of polyps in the colon. The alignment allows the company to proceed with the late-stage study as planned.

In related developments, Morgan Stanley lowered its price target for the stock to $5.60 from $5.90. J.P. Morgan maintained a Buy rating on the shares, while Bank of America Merrill Lynch initiated coverage on the company. Recursion also announced its participation in upcoming investor conferences and the signing of Dr. Renata Moon for a publication titled "White Coats, Red Flags."

What The Data Shows

The stock opened at $2.80, representing a 2.9% gap from the prior close of $2.72. The session high reached $2.92 at 9:40 AM ET, while the low was $2.77 at 9:30 AM ET. Trading volume stood at 2.6 million shares, which is 0.1 times the three-month daily average.

Recursion Pharmaceuticals has a market capitalization of $1.8 billion and is currently unprofitable, with a trailing twelve-month EPS of -0.89. Revenue increased by 56.2% over the same period. The stock has a beta of 1.15 and trades within a 52-week range of $2.50 to $5.24. Over the last eight sessions, the stock fell 22.7%, moving from $3.52 to $2.72. The company printed five fresh 52-week highs on November 18, 2026. Recent insider activity includes five sales totaling $701,000 over the last 90 days, with no buys recorded.

What To Watch

Investors will monitor the execution of the Phase 3 trial for REC-4881 as the next major catalyst. The upcoming participation in investor conferences may also provide additional insights into the company's strategic direction.

AI-assisted analysis composed exclusively from headlines and data on the Top Tier newswire. Public view is delayed 4 hours from real time. Not financial advice.

RXRX by the numbers

Last: $2.91Session: +6.99%7 sessions: -25.76%Coverage: 6 stories / 4 sourcesAI sentiment: 61/100 (bullish)Mkt cap: $1.8B52w: $2.50 to $5.24
RXRX · Nov 18 session (5-min) · +5.51% vs prior close · updated 8:53 PM ET
$2.70$2.85$3.00prev close $2.72$2.877:00 AM10:13 AM1:27 PM4:41 PM7:55 PM7:00 AM · $2.797:05 AM · $2.797:10 AM · $2.797:15 AM · $2.807:20 AM · $2.817:25 AM · $2.827:30 AM · $2.817:35 AM · $2.817:40 AM · $2.817:45 AM · $2.817:50 AM · $2.807:55 AM · $2.818:00 AM · $2.808:05 AM · $2.808:10 AM · $2.818:15 AM · $2.808:20 AM · $2.818:25 AM · $2.808:30 AM · $2.818:35 AM · $2.828:40 AM · $2.828:45 AM · $2.818:50 AM · $2.828:55 AM · $2.819:00 AM · $2.809:05 AM · $2.809:10 AM · $2.809:15 AM · $2.809:20 AM · $2.809:25 AM · $2.799:30 AM · $2.909:35 AM · $2.899:40 AM · $2.949:45 AM · $2.949:50 AM · $2.979:55 AM · $2.9410:00 AM · $2.9910:05 AM · $2.9810:10 AM · $2.9810:15 AM · $2.9610:20 AM · $2.9510:25 AM · $2.9410:30 AM · $2.9110:35 AM · $2.9010:40 AM · $2.8910:45 AM · $2.8810:50 AM · $2.8810:55 AM · $2.8811:00 AM · $2.8711:05 AM · $2.8711:10 AM · $2.8511:15 AM · $2.8511:20 AM · $2.8711:25 AM · $2.8811:30 AM · $2.8711:35 AM · $2.8711:40 AM · $2.8611:45 AM · $2.8711:50 AM · $2.8611:55 AM · $2.8812:00 PM · $2.9012:05 PM · $2.8712:10 PM · $2.8712:15 PM · $2.9012:20 PM · $2.9412:25 PM · $2.9412:30 PM · $2.9612:35 PM · $2.9412:40 PM · $2.9412:45 PM · $2.9412:50 PM · $2.9412:55 PM · $2.941:00 PM · $2.941:05 PM · $2.941:10 PM · $2.931:15 PM · $2.921:20 PM · $2.921:25 PM · $2.921:30 PM · $2.921:35 PM · $2.921:40 PM · $2.921:45 PM · $2.921:50 PM · $2.921:55 PM · $2.922:00 PM · $2.912:05 PM · $2.912:10 PM · $2.922:15 PM · $2.902:20 PM · $2.902:25 PM · $2.902:30 PM · $2.892:35 PM · $2.892:40 PM · $2.872:45 PM · $2.832:50 PM · $2.832:55 PM · $2.813:00 PM · $2.883:05 PM · $2.883:10 PM · $2.873:15 PM · $2.863:20 PM · $2.853:25 PM · $2.843:30 PM · $2.843:35 PM · $2.833:40 PM · $2.833:45 PM · $2.833:50 PM · $2.833:55 PM · $2.834:00 PM · $2.824:05 PM · $2.824:15 PM · $2.824:20 PM · $2.814:25 PM · $2.814:30 PM · $2.814:35 PM · $2.814:40 PM · $2.824:45 PM · $2.814:50 PM · $2.814:55 PM · $2.825:00 PM · $2.825:05 PM · $2.815:10 PM · $2.825:15 PM · $2.825:20 PM · $2.825:25 PM · $2.825:30 PM · $2.835:35 PM · $2.835:40 PM · $2.825:45 PM · $2.825:50 PM · $2.835:55 PM · $2.826:05 PM · $2.856:10 PM · $2.856:15 PM · $2.846:20 PM · $2.836:25 PM · $2.846:30 PM · $2.856:35 PM · $2.856:40 PM · $2.856:45 PM · $2.856:55 PM · $2.837:00 PM · $2.847:20 PM · $2.867:25 PM · $2.857:30 PM · $2.867:35 PM · $2.857:40 PM · $2.887:45 PM · $2.897:50 PM · $2.907:55 PM · $2.87
AI sentiment, last 36h · averaged over 6 stories · 61/100 bullish
AI sentiment 61/100 (bullish)0 · bearish50bullish · 100

The headlines behind the move

Story flow · 6 stories on the wire, last 36h · hover or tap a dot for the headline
36h ago24h ago12h agopublishStockTitan · sentiment 64 · Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous PolyposisStockTitan · 64Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-488…The Fly · sentiment 63 · Recursion Pharmaceuticals aligns with FDA on trial of REC-4881The Fly · 63Recursion Pharmaceuticals aligns with FDA on trial of REC-4881GuruFocus · sentiment 64 · Recursion (RXRX) Secures FDA Agreement on Phase 3 Trial Design for REC-4881 in FAPGuruFocus · 64Recursion (RXRX) Secures FDA Agreement on Phase 3 Trial Design for REC-4881 in FAPSeeking Alpha · sentiment 64 · Recursion aligns with FDA on late-stage trial design for rare disease therapySeeking Alpha · 64Recursion aligns with FDA on late-stage trial design for rare disease therapyThe Fly · sentiment 34 · Recursion Pharmaceuticals price target lowered to $5.60 from $5.90 at Morgan StanleyThe Fly · 34Recursion Pharmaceuticals price target lowered to $5.60 from $5.90 at Morgan StanleyGuruFocus · sentiment 74 · Recursion Pharmaceuticals (RXRX) Gains FDA Nod for Phase 3 Trial in Rare Disease TreatmentGuruFocus · 74Recursion Pharmaceuticals (RXRX) Gains FDA Nod for Phase 3 Trial in Rare Disease Treatment
2d agoGuruFocusBULLISH 74Product/PR

Recursion Pharmaceuticals (RXRX) Gains FDA Nod for Phase 3 Trial in Rare Disease Treatment

2d agoThe FlyBEARISH 34Analyst

Recursion Pharmaceuticals price target lowered to $5.60 from $5.90 at Morgan Stanley

2d agoSeeking AlphaBULLISH 64Product/PR

Recursion aligns with FDA on late-stage trial design for rare disease therapy

Recursion (RXRX) aligns with the FDA regarding a late-stage trial design for its rare disease therapy, REC-4881. Read more here.

2d agoGuruFocusBULLISH 64Product/PR

Recursion (RXRX) Secures FDA Agreement on Phase 3 Trial Design for REC-4881 in FAP

2d agoThe FlyBULLISH 63Product/PR

Recursion Pharmaceuticals aligns with FDA on trial of REC-4881

2d agoStockTitanBULLISH 64Product/PR

Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis

Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →

More on RXRX: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.

Earlier RXRX move explainers: 2026-11-18 · 2026-10-16 · 2026-10-15